Skip to content

Elderberries and Obesity

Supporting Local Agriculture Via Clinical Research: Human Studies With Elderberries to Improve Biomarkers of Obesity

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05723497
Enrollment
10
Registered
2023-02-10
Start date
2021-07-27
Completion date
2022-09-02
Last updated
2023-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fuel Management

Brief summary

Previous studies in humans indicate that anthocyanin-rich berries can positively alter fat oxidation and insulin sensitivity. This study will determine if this is also true with elderberries, which are a more concentrated source of anthocyanins compared to other commonly consumed berries.

Interventions

Participants will consume elderberry juice 1-week.

OTHERPlacebo beverage

Participants will consume placebo for 1-week.

Sponsors

Washington State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Women and Men between 22 and 75 years of age with a body mass index of 25 kg/m2 or above.

Exclusion criteria

* Are not fully vaccinated against COVID-19 (at least 2-weeks out from final dose at time of staff meeting) * Have a body mass index less than 25 kg/m2 * Are younger than 22 years of age, or older than 75 years of age * Pregnant, lactating, or intending to become pregnant during the study period, or have given birth in the past year * Known allergy or intolerance to elderberries * History of bariatric surgery or nutrient malabsorption disease (such as celiac disease) or other metabolic disorders requiring a special diet that is not in accord with the diet behavior requested for this study * Adherence to restrictive (vegetarian or vegan) or extreme (fad \[ex. Ketogenic or Atkins\] or quick weight loss/gain) diet patterns and unwillingness to consume a conventional, omnivorous diet and maintain body weight * Habitual use of tobacco or marijuana (including vaping) products in the last 6 months * Diagnosis or treatment of cancer in the past 3 years * Crohn's disease or diverticulitis * Suspected or known strictures, fistulas or physiological/mechanical GI obstruction * Use of certain medications (prescription or over-the-counter) that may interfere with the study objectives, including blood thinning medications * Type 2 diabetes requiring the use of medication * Fasting blood glucose \> 125 mg/dL * Unable or unwilling to give informed consent or communicate with study staff * Self-report of alcohol or substance abuse within the past 12 months and/or current treatment for these problems (long-term participation in Alcoholics Anonymous is not an exclusion) * Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

Design outcomes

Primary

MeasureTime frameDescription
Substrate oxidation3.5 hoursParticipants will be monitored by a metabolic cart at rest and while walking
Glucose tolerance/insulin sensitivity3 hoursBlood will be collected following a meal tolerance test

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026